BioSpace News Archive

Lexicon Pharmaceuticals, Inc., reported financial results and provided a business update for the three months ended March 31, 2020.

The primary analysis of investigational, once-nightly FT218 at 9 g demonstrated highly statistically significant (p<0.001), and clinically meaningful improvement across all three co-primary endpoints compared to placebo

CareDx, Inc. announced the online delivery of the content originally meant for showcase at the now-postponed annual European Immunogenetics and Histocompatibility Conference that was scheduled for Apr 26-29, 2020 in Glasgow, Scotland.

Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, announced positive immunogenicity data from its preclinical study for the Company’s COVID-19 Vaccine.

Preliminary data in moderate-to-severe COVID-19 patients treated with opaganib show measurable clinical improvement in all six patients analyzed, including decreased requirement for supplemental oxygenation, higher lymphocyte counts and decreased CRP

Kamada is Responsible for Product Development, Manufacturing, Clinical Development, and Regulatory Submissions, as well as Distribution in Territories not under Kedrion’s Responsibility

Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced “critical” group with Kevzara higher-dose versus placebo and discontinuing less advanced “severe” group

Regeneron Pharmaceuticals, Inc. and Sanofi announced the primary endpoint of overall survival was met in a Phase 3 trial comparing the PD-1 inhibitor Libtayo® to platinum-doublet chemotherapy in patients with first-line locally advanced or metastatic non-small cell lung cancer that tested positive for PD-L1 in ≥50% of tumor cells.

Partnerships and programs address the social determinants of health across Mississippi

Global Cord Blood Corporation, China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, provided an update on the impact of the 2019 novel coronavirus on the Company’s expected fiscal 2021 operations.